Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $12.77 and last traded at $13.29, with a volume of 499471 shares trading hands. The stock had previously closed at $13.06.
Takeda Pharmaceutical Stock Up 2.5 %
The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.55 and a current ratio of 1.06. The stock has a market cap of $42.35 billion, a PE ratio of 20.26, a price-to-earnings-growth ratio of 3.05 and a beta of 0.56. The company's 50-day moving average price is $13.82 and its 200 day moving average price is $14.09.
Institutional Investors Weigh In On Takeda Pharmaceutical
Several hedge funds and other institutional investors have recently modified their holdings of TAK. Mondrian Investment Partners LTD increased its position in Takeda Pharmaceutical by 47.9% in the first quarter. Mondrian Investment Partners LTD now owns 12,079,962 shares of the company's stock worth $169,119,000 after buying an additional 3,912,569 shares in the last quarter. OLD Mission Capital LLC lifted its holdings in Takeda Pharmaceutical by 1,440.9% during the fourth quarter. OLD Mission Capital LLC now owns 1,041,526 shares of the company's stock valued at $14,863,000 after purchasing an additional 973,935 shares in the last quarter. Brandes Investment Partners LP boosted its position in shares of Takeda Pharmaceutical by 47.1% in the fourth quarter. Brandes Investment Partners LP now owns 2,651,265 shares of the company's stock worth $37,834,000 after purchasing an additional 849,229 shares during the period. XY Capital Ltd increased its stake in shares of Takeda Pharmaceutical by 432.5% in the fourth quarter. XY Capital Ltd now owns 765,137 shares of the company's stock worth $10,919,000 after purchasing an additional 621,440 shares in the last quarter. Finally, Capital Research Global Investors increased its stake in shares of Takeda Pharmaceutical by 3.6% in the fourth quarter. Capital Research Global Investors now owns 14,297,805 shares of the company's stock worth $204,030,000 after purchasing an additional 503,446 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Recommended Stories
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
